OncoMatch/Clinical Trials/NCT06677190
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Is NCT06677190 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Belzutifan for ovarian cancer.
Treatment: Belzutifan — The purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with clear cell gynecologic malignancy, including but not limited to, ovarian cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, or endometriosis-related cancer. The name of the study drug involved in this study is: \- Belzutifan (a type of Hypoxia-Inducible Factor-2 alpha (HIF-2a) inhibitor)
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Endometrial Cancer
Cervical Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — primary management
Participants must have received at least one prior platinum-based chemotherapeutic regimen for primary management of disease.
Cannot have received: HIF-2a inhibitor (belzutifan)
Prior use of Belzutifan or another HIF-2a inhibitor.
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,500/mcL; Hemoglobin ≥ 10.0 g/dL (without use of erythropoietin; without packed red blood cell (RBC) transfusion within preceding 2 weeks); Platelets ≥ 100,000/mcL
Kidney function
Creatinine ≤ 1.5 x institutional ULN OR estimated creatinine clearance (CrCl) by the Cockcroft-Gault formula ≥51mL/min if creatinine > 1.5 x institutional ULN or institutional standard method
Liver function
Total bilirubin ≤ 1.5 x institutional ULN OR direct bilirubin ≤ ULN for participants with total bilirubin levels > 1.5 ULN; AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN (in the absence of liver metastases) or ≤ 5 x institutional ULN (in the presence of liver metastases)
Participants must meet the following organ and marrow function as defined below: ... (see full criteria above)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify